Top Articles

Lisbon 2018: Report on Symposium 6:   Coma: neuromodulation, imaging and neurobiology June 18th, 2018 by Antonella Macerollo This symposium was chaired by Prof Laureys, Belgium, and Dr Diserens, Switzerland. Dr Kondziella from Denmark gave the first presentation titled: Mechanisms of… Continue Reading

Overarching Theme: Molecular and genetic therapies for neurogenetic disorders   18 June 2018   By Tom Jenkins   This plenary session focused on perhaps the most exciting area of clinical neurology in recent years, at least in terms of therapeutic breakthroughs and… Continue Reading

Prof. Günther Deuschl, President of the EAN, also welcomed everybody. He highlighted some recent important studies published by European researchers, the celebration of the Brain Prize in Europe, and some EAN achievements such as the guidelines project. The EAN is also particularly interested in assessing the burden of neurological diseases in Europe.

Recently, EAN held elections of the Scientific Panel Management groups. All Panel Members - institutional that are nominated by a national society, and individual - were invited to send in their applications. The Scientific Committee received altogether 163 applications, from 30 different countries (59 female and 104 male applicants).

The year of 1949 was a celebrating year for Neurosciences in Portugal, since our professor of Neurology Egas Moniz was awarded the Nobel Prize of Medicine and Physiology, an important recognition of his neuroscience research. This was a mark that very much inspired the interest of our medical school on neurosciences.

Scientific plagiarism is defined as using or closely imitating scientific content from an original author without clear reference and/or authorization. Plagiarism can be complete or partial, in the original or translated version or limited to paraphrases of the original text. A textual repetition of one’s own work in subsequent submissions is considered self-plagiarism and should be avoided or at least accompanied by proper referencing to one’s prior work.

As in the previous years, EANpages asked EAN committee members, panel chairs, and invited speakers  which session one should not miss at the upcoming congress in Lisbon 2018. Please find their answers below!

Sub-committee and working group chairs
Members of committees Are you eager to shape the future of Neurology in Europe in parallel to developing your professional standing and leadership skills? Following the formation of a new Executive Board of the EAN… Continue Reading

Dear members of the EAN, following the election of 5 members of the EAN Executive Board in Lisbon this new Board will appoint the chair of the education committee and the chair of the program committee. We therefore solicit the… Continue Reading

The celebrations of the Dystonia Europe 25th annniversary kicked off with a special lunch event in the European Parliament on 12 April. The 65 guests were welcomed by the Finnish Member of the European Parliament (MEP) Ms. Merja Kyllönen.  She… Continue Reading

  The democratic body of the European Academy of Neurology (EAN) is the assembly of delegates, which acts as the parliament of the EAN. This assembly meets once a year, usually on Saturday, during the annual meeting. The 4 major… Continue Reading

As in the previous years, EANpages asked EAN committee members, panel chairs, and invited speakers  which session one should not miss at the upcoming congress in Lisbon 2018. Please find their answers below!   Rolf Fronczek, MD, PhD
Dept. of… Continue Reading

  Portugal has a long tradition in the study of behavioral disorders, dating back to the work of Egas Moniz and his attempt to improve some psychosis with psychosurgery. In the early 1970’s Antonio Damasio, who was taking his PhD… Continue Reading

For May 2018, we have selected: Kappos L, Bar-Or A, Cree BAC, et al., for the EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet Neurol 2018;391:1263-1273. Secondary progressive multiple sclerosis (SPMS) is characterized by a previous history of relapsing remitting MS (RRMS) and the continuous progression of disability over the years typically without relapses.